John DeLuca

481 total citations
9 papers, 365 citations indexed

About

John DeLuca is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, John DeLuca has authored 9 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in John DeLuca's work include Renal cell carcinoma treatment (7 papers), Economic and Financial Impacts of Cancer (2 papers) and Renal and related cancers (2 papers). John DeLuca is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Economic and Financial Impacts of Cancer (2 papers) and Renal and related cancers (2 papers). John DeLuca collaborates with scholars based in United States. John DeLuca's co-authors include Robert J. Motzer, Nicole Ishill, G. Varuni Kondagunta, Jennifer Bacik, Sujata Patil, Lawrence H. Schwartz, Ellen A. Ronnen, Darren R. Feldman, Maria I. Carlo and Chung‐Han Lee and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Oncologist.

In The Last Decade

John DeLuca

9 papers receiving 362 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John DeLuca United States 6 227 101 81 70 70 9 365
Laura K. Nolden United States 6 235 1.0× 77 0.8× 33 0.4× 132 1.9× 47 0.7× 7 401
Lucia Raimondo Italy 8 204 0.9× 105 1.0× 66 0.8× 185 2.6× 55 0.8× 15 387
Peter Houghton United States 8 171 0.8× 165 1.6× 25 0.3× 150 2.1× 76 1.1× 20 400
Astrid Schott Germany 6 213 0.9× 72 0.7× 73 0.9× 171 2.4× 33 0.5× 8 422
Daniel Antunes Moreno Brazil 11 293 1.3× 31 0.3× 36 0.4× 87 1.2× 73 1.0× 34 461
Turgut Dogruluk United States 7 233 1.0× 81 0.8× 25 0.3× 104 1.5× 102 1.5× 8 369
Ruud van der Noll Netherlands 12 318 1.4× 99 1.0× 50 0.6× 213 3.0× 59 0.8× 20 463
Giulia Orlando Italy 10 322 1.4× 49 0.5× 25 0.3× 121 1.7× 76 1.1× 30 484
Kerstin Unterschemmann Germany 6 220 1.0× 95 0.9× 23 0.3× 171 2.4× 205 2.9× 8 485
Guosheng Lin China 11 276 1.2× 109 1.1× 57 0.7× 94 1.3× 112 1.6× 25 555

Countries citing papers authored by John DeLuca

Since Specialization
Citations

This map shows the geographic impact of John DeLuca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John DeLuca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John DeLuca more than expected).

Fields of papers citing papers by John DeLuca

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John DeLuca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John DeLuca. The network helps show where John DeLuca may publish in the future.

Co-authorship network of co-authors of John DeLuca

This figure shows the co-authorship network connecting the top 25 collaborators of John DeLuca. A scholar is included among the top collaborators of John DeLuca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John DeLuca. John DeLuca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Carlo, Maria I., Ana M. Molina, Yulia Lakhman, et al.. (2016). A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. The Oncologist. 21(7). 787–788d. 81 indexed citations
2.
OʼBrien, Bridget C., Benjamin Dyer, John DeLuca, & Bryan K. Richmond. (2014). Streptococcus bovis bacteremia as the initial presentation of carcinoma of the gallbladder.. PubMed. 110(2). 32–3. 3 indexed citations
3.
Patil, Sujata, Nicole Ishill, John DeLuca, & Robert J. Motzer. (2009). Stage migration and increasing proportion of favorable‐prognosis metastatic renal cell carcinoma patients. Cancer. 116(2). 347–354. 41 indexed citations
4.
Feldman, Darren R., G. Varuni Kondagunta, Lawrence H. Schwartz, et al.. (2008). Phase II Trial of Pegylated Interferon-α2b in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer. 6(1). 25–30. 17 indexed citations
5.
Ishill, Nicole, et al.. (2008). Trends in Memorial Sloan-Kettering Cancer Center risk group distribution according to treatment year for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 26(15_suppl). 5092–5092. 2 indexed citations
6.
Patel, Premal H., G. Varuni Kondagunta, Lawrence H. Schwartz, et al.. (2007). Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. Investigational New Drugs. 26(3). 273–276. 16 indexed citations
7.
Ronnen, Ellen A., G. Varuni Kondagunta, Nicole Ishill, et al.. (2006). A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Investigational New Drugs. 24(6). 543–546. 125 indexed citations
8.
Kondagunta, G. Varuni, Jennifer Bacik, Joel Sheinfeld, et al.. (2006). Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors. Journal of Clinical Oncology. 25(1). 85–90. 77 indexed citations
9.
Kondagunta, G. Varuni, Jennifer Bacik, Nicole Ishill, et al.. (2006). Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response. Journal of Clinical Oncology. 24(18_suppl). 4528–4528. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura K. Nolden Breakdown of academic impact, for papers by Lucia Raimondo Breakdown of academic impact, for papers by Peter Houghton Breakdown of academic impact, for papers by Astrid Schott Breakdown of academic impact, for papers by Daniel Antunes Moreno Breakdown of academic impact, for papers by Turgut Dogruluk Breakdown of academic impact, for papers by Ruud van der Noll Breakdown of academic impact, for papers by Giulia Orlando Breakdown of academic impact, for papers by Kerstin Unterschemmann Breakdown of academic impact, for papers by Guosheng Lin
Rankless by CCL
2026